Plasminogen activator, Molecular biology, Urokinase, Biochemistry and Urokinase receptor are his primary areas of study. Peter A. Andreasen studies Plasminogen activator inhibitor-1 which is a part of Plasminogen activator. His Molecular biology research is multidisciplinary, incorporating elements of Amino acid, Peptide sequence and Zymography.
The various areas that Peter A. Andreasen examines in his Urokinase study include Enzyme inhibitor, Enzyme and Mammary gland. His work carried out in the field of Urokinase receptor brings together such families of science as Plasminogen activator inhibitor-2, Cell surface receptor, Tumor progression, Extracellular matrix and Receptor expression. His Proteolysis research includes elements of Zymogen and Somatomedin B.
Peter A. Andreasen spends much of his time researching Plasminogen activator, Biochemistry, Molecular biology, Plasminogen activator inhibitor-1 and Serpin. His Plasminogen activator research focuses on Urokinase receptor in particular. His Urokinase receptor study incorporates themes from Cell surface receptor and Cell biology.
His research investigates the link between Molecular biology and topics such as Cell culture that cross with problems in Plasminogen Inactivators. His research on Plasminogen activator inhibitor-1 also deals with topics like
His primary areas of study are Biochemistry, Plasminogen activator, Serine protease, Proteases and Protease. His study in Biochemistry is interdisciplinary in nature, drawing from both Plasminogen activator inhibitor-1 and Aptamer. Peter A. Andreasen studies Plasminogen activator, focusing on Urokinase receptor in particular.
His Proteases research is multidisciplinary, relying on both Serine, Zymogen, Hepatocyte Growth Factor Activator, Activator and Kringle domain. Peter A. Andreasen usually deals with Protease and limits it to topics linked to Protein folding and Mutation, Proteolysis and Conserved sequence. His biological study spans a wide range of topics, including Molecular biology, Stromal cell and Intravasation, Metastasis.
His scientific interests lie mostly in Biochemistry, Plasminogen activator, Serpin, Plasminogen activator inhibitor-1 and Vitronectin. He works mostly in the field of Biochemistry, limiting it down to concerns involving Aptamer and, occasionally, RNA and Systematic evolution of ligands by exponential enrichment. His work is dedicated to discovering how Plasminogen activator, Urokinase are connected with Cell biology and other disciplines.
Peter A. Andreasen has included themes like Wild type, Fibrinolysis, Conformational change and Binding site in his Serpin study. The Plasminogen activator inhibitor-1 study which covers Biophysics that intersects with Hydrogen–deuterium exchange. His research in Urokinase receptor intersects with topics in Cancer cell, Metastasis and Plasmin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Plasminogen activators, tissue degradation, and cancer.
K Danø;P A Andreasen;J Grøndahl-Hansen;P Kristensen.
Advances in Cancer Research (1985)
THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR SYSTEM IN CANCER METASTASIS: A REVIEW
Peter A. Andreasen;Lars Kjøller;Lise Christensen;Michael J. Duffy.
International Journal of Cancer (1997)
The plasminogen activation system in tumor growth, invasion, and metastasis.
P. A. Andreasen;R. Egelund;H. H. Petersen.
Cellular and Molecular Life Sciences (2000)
Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
A Nykjaer;C M Petersen;B Møller;P H Jensen.
Journal of Biological Chemistry (1992)
Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta.
Marikki Laiho;Olli Saksela;Olli Saksela;Peter A. Andreasen;Jorma Keski-Oja;Jorma Keski-Oja.
Journal of Cell Biology (1986)
Plasminogen activator inhibitors: hormonally regulated serpins
Peter A. Andreasen;Birgitte Georg;Leif R. Lund;Andrea Riccio.
Molecular and Cellular Endocrinology (1990)
cDNA cloning of human plasminogen activator-inhibitor from endothelial cells
D Ginsburg;R Zeheb;A Y Yang;U M Rafferty.
Journal of Clinical Investigation (1986)
UROKINASE-PLASMINOGEN ACTIVATOR, A NEW AND INDEPENDENT PROGNOSTIC MARKER IN BREAST CANCER
Michael J. Duffy;David Reilly;Cathriona O'Sullivan;Niall O'Higgins.
Cancer Research (1990)
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells
J Pöllänen;O Saksela;EM Salonen;P Andreasen.
Journal of Cell Biology (1987)
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
P A Andreasen;L S Nielsen;P Kristensen;J Grøndahl-Hansen.
Journal of Biological Chemistry (1986)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: